Literature DB >> 32633354

LncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT.

J-H Wu1, K Xu, J-H Liu, L-L Du, X-S Li, Y-M Su, J-C Liu.   

Abstract

OBJECTIVE: The purpose of this study was to investigate the expression profile of long non-coding RNA (lncRNA) MT1JP in hepatocellular carcinoma (HCC), and to explore the relationship between its expression level and the clinical indicators, as well as the prognosis of HCC patients. PATIENTS AND METHODS: In this study, the expression level of MT1JP in 45 pairs of tumor tissue specimens and paracancerous ones collected from HCC patients were examined through quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) method, and the interplay between MT1JP expression and clinical indicators, as well as the prognosis of HCC patients, was also analyzed. Meanwhile, the expression of MT1JP in HCC cell lines was further verified by qRT-PCR. In addition, MT1JP overexpression model was constructed using lentivirus in HCC cell lines (Hub7 and HepG2), and then, Cell Counting Kit-8 (CCK-8), cell colony formation assay, and flow cytometry were performed to examine the impact of MT1JP on the HCC cell functions. Additionally, whether MT1JP exerts its biological characteristics through protein kinase B (AKT) was finally explored.
RESULTS: In this experiment, qRT-PCR results showed that the expression level of lncRNA MT1JP in tumor tissues of HCC patients was remarkably lower than that in adjacent tissues, and the difference was statistically significant. Meanwhile, compared with patients with high expression of MT1JP, patients with low expression of MT1JP had a higher pathological staging and a lower overall survival rate. In addition, overexpression of MT1JP remarkably attenuated the proliferation ability of HCC cells but enhanced cell apoptosis rate at the same time. Finally, Western blot results revealed that the overexpression of MT1JP may markedly reduce the AKT expression, thereby suppressing the malignant progression of HCC.
CONCLUSIONS: LncRNA MT1JP expression is remarkably decreased in HCC tumor tissue samples, which is associated with pathological stage and poor prognosis of HCC patients. In addition, MT1JP may inhibit the malignant progression of HCC by downregulating AKT.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32633354     DOI: 10.26355/eurrev_202006_21651

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Role of lncRNA NR2F1-AS1 and lncRNA H19 Genes in Hepatocellular Carcinoma and Their Effects on Biological Function of Huh-7.

Authors:  Wen-Chao Ji; Guang-Jian Bao; Fang-Wu Yang; Lei Sun; Rui Han
Journal:  Cancer Manag Res       Date:  2021-02-03       Impact factor: 3.989

Review 2.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

3.  Integrating the Epigenome and Transcriptome of Hepatocellular Carcinoma to Identify Systematic Enhancer Aberrations and Establish an Aberrant Enhancer-Related Prognostic Signature.

Authors:  Peng Huang; Bin Zhang; Junsheng Zhao; Ming D Li
Journal:  Front Cell Dev Biol       Date:  2022-03-01

Review 4.  The functions of long noncoding RNAs on regulation of F-box proteins in tumorigenesis and progression.

Authors:  Lu Xia; Jingyun Chen; Min Huang; Jie Mei; Min Lin
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

5.  lncRNA MT1JP-overexpression abolishes the silencing of PTEN by miR-32 in hepatocellular carcinoma.

Authors:  Shuhua Zhang; Jianqun Xu; Qing Chen; Fan Zhang; Hongjuan Wang; Hongrong Guo
Journal:  Oncol Lett       Date:  2021-06-15       Impact factor: 2.967

6.  Identification of Candidate lncRNA and Pseudogene Biomarkers Associated with Carbon-Nanotube-Induced Malignant Transformation of Lung Cells and Prediction of Potential Preventive Drugs.

Authors:  Guangtao Chang; Dongli Xie; Jianchen Hu; Tong Wu; Kangli Cao; Xiaogang Luo
Journal:  Int J Environ Res Public Health       Date:  2022-03-02       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.